Down-regulation of PPARγ2-induced adipogenesis by PEGylated conjugated linoleic acid as the pro-drug

Attenuation of lipid accumulation and reduction of apoptosis

Hyun-Seuk Moon, H. G. Lee, J. H. Seo, C. S. Chung, T. G. Kim, I. Y. Kim, K. W. Lim, S. J. Seo, Y. J. Choi, C. S. Cho

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

This study is designed to evaluate whether the PEGylated conjugated linoleic acid (PCLA) as the pro-drug can have favorable stability, bioavailability, and anti-adipogenic activity in 3T3-L1 cells for anti-obesity when compared with conjugated linoleic acid (CLA) itself. The CLA was simply coupled to poly(ethylene glycol) (PEG) at the melting state without solvents or catalysts through ester linkages between the carboxylic group of CLA and the hydroxyl group of PEG. To confirm of PCLA as the pro-drug, CLA release from PCLA was investigated by using high-performance liquid chromatographic (HPLC), showing that CLA release from PCLA was almost 90% in a nearly continuous fashion over the next 75 h. Apoptosis was promoted by both CLA- and PCLA-treatments with increasing concentrations. However, the level of cell apoptosis induced by PCLA was lower than that induced by CLA owing to the biocompatible and hydrophilic properties of PEG. Moreover, the PCLA decreased glycerol-3-phosphate dehydrogenase (GPDH) activity in 3T3-L1 cells by acting upon major adipocyte marker proteins such as PPARγ2, C/EBPα, and aP2 modulators. Furthermore, either CLA or PCLA stimulated basal, but not isoproterenol-sensitive, lipolysis in our cell model, suggesting that both CLA and PCLA may stimulate lipolysis via hormone sensitive lipase (HSL)-independent mechanisms. These results suggest that the PCLA may prove to be a stable pro-drug to control the deposition of fat in the human body, and that the anti-adipogenic effect of the PCLA on 3T3-L1 cells will offer a challenging approach for anti-obesity.

Original languageEnglish
Pages (from-to)19-29
Number of pages11
JournalArchives of Biochemistry and Biophysics
Volume456
Issue number1
DOIs
Publication statusPublished - 2006 Dec 1
Externally publishedYes

Fingerprint

Conjugated Linoleic Acids
Adipogenesis
Prodrugs
Down-Regulation
Apoptosis
Lipids
3T3-L1 Cells
Polyethylene glycols
Lipolysis
Obesity
Sterol Esterase
Glycerolphosphate Dehydrogenase

Keywords

  • Adipocyte differentiation
  • Anti-obesity
  • Conjugated linoleic acid (CLA)
  • Lipolysis
  • PEGylation
  • Poly(ethylene glycol) (PEG)
  • Pro-drug

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Down-regulation of PPARγ2-induced adipogenesis by PEGylated conjugated linoleic acid as the pro-drug : Attenuation of lipid accumulation and reduction of apoptosis. / Moon, Hyun-Seuk; Lee, H. G.; Seo, J. H.; Chung, C. S.; Kim, T. G.; Kim, I. Y.; Lim, K. W.; Seo, S. J.; Choi, Y. J.; Cho, C. S.

In: Archives of Biochemistry and Biophysics, Vol. 456, No. 1, 01.12.2006, p. 19-29.

Research output: Contribution to journalArticle

Moon, Hyun-Seuk ; Lee, H. G. ; Seo, J. H. ; Chung, C. S. ; Kim, T. G. ; Kim, I. Y. ; Lim, K. W. ; Seo, S. J. ; Choi, Y. J. ; Cho, C. S. / Down-regulation of PPARγ2-induced adipogenesis by PEGylated conjugated linoleic acid as the pro-drug : Attenuation of lipid accumulation and reduction of apoptosis. In: Archives of Biochemistry and Biophysics. 2006 ; Vol. 456, No. 1. pp. 19-29.
@article{823d6fbb3a9e48579f87781de4bc8d52,
title = "Down-regulation of PPARγ2-induced adipogenesis by PEGylated conjugated linoleic acid as the pro-drug: Attenuation of lipid accumulation and reduction of apoptosis",
abstract = "This study is designed to evaluate whether the PEGylated conjugated linoleic acid (PCLA) as the pro-drug can have favorable stability, bioavailability, and anti-adipogenic activity in 3T3-L1 cells for anti-obesity when compared with conjugated linoleic acid (CLA) itself. The CLA was simply coupled to poly(ethylene glycol) (PEG) at the melting state without solvents or catalysts through ester linkages between the carboxylic group of CLA and the hydroxyl group of PEG. To confirm of PCLA as the pro-drug, CLA release from PCLA was investigated by using high-performance liquid chromatographic (HPLC), showing that CLA release from PCLA was almost 90{\%} in a nearly continuous fashion over the next 75 h. Apoptosis was promoted by both CLA- and PCLA-treatments with increasing concentrations. However, the level of cell apoptosis induced by PCLA was lower than that induced by CLA owing to the biocompatible and hydrophilic properties of PEG. Moreover, the PCLA decreased glycerol-3-phosphate dehydrogenase (GPDH) activity in 3T3-L1 cells by acting upon major adipocyte marker proteins such as PPARγ2, C/EBPα, and aP2 modulators. Furthermore, either CLA or PCLA stimulated basal, but not isoproterenol-sensitive, lipolysis in our cell model, suggesting that both CLA and PCLA may stimulate lipolysis via hormone sensitive lipase (HSL)-independent mechanisms. These results suggest that the PCLA may prove to be a stable pro-drug to control the deposition of fat in the human body, and that the anti-adipogenic effect of the PCLA on 3T3-L1 cells will offer a challenging approach for anti-obesity.",
keywords = "Adipocyte differentiation, Anti-obesity, Conjugated linoleic acid (CLA), Lipolysis, PEGylation, Poly(ethylene glycol) (PEG), Pro-drug",
author = "Hyun-Seuk Moon and Lee, {H. G.} and Seo, {J. H.} and Chung, {C. S.} and Kim, {T. G.} and Kim, {I. Y.} and Lim, {K. W.} and Seo, {S. J.} and Choi, {Y. J.} and Cho, {C. S.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/j.abb.2006.10.002",
language = "English",
volume = "456",
pages = "19--29",
journal = "Archives of Biochemistry and Biophysics",
issn = "0003-9861",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Down-regulation of PPARγ2-induced adipogenesis by PEGylated conjugated linoleic acid as the pro-drug

T2 - Attenuation of lipid accumulation and reduction of apoptosis

AU - Moon, Hyun-Seuk

AU - Lee, H. G.

AU - Seo, J. H.

AU - Chung, C. S.

AU - Kim, T. G.

AU - Kim, I. Y.

AU - Lim, K. W.

AU - Seo, S. J.

AU - Choi, Y. J.

AU - Cho, C. S.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - This study is designed to evaluate whether the PEGylated conjugated linoleic acid (PCLA) as the pro-drug can have favorable stability, bioavailability, and anti-adipogenic activity in 3T3-L1 cells for anti-obesity when compared with conjugated linoleic acid (CLA) itself. The CLA was simply coupled to poly(ethylene glycol) (PEG) at the melting state without solvents or catalysts through ester linkages between the carboxylic group of CLA and the hydroxyl group of PEG. To confirm of PCLA as the pro-drug, CLA release from PCLA was investigated by using high-performance liquid chromatographic (HPLC), showing that CLA release from PCLA was almost 90% in a nearly continuous fashion over the next 75 h. Apoptosis was promoted by both CLA- and PCLA-treatments with increasing concentrations. However, the level of cell apoptosis induced by PCLA was lower than that induced by CLA owing to the biocompatible and hydrophilic properties of PEG. Moreover, the PCLA decreased glycerol-3-phosphate dehydrogenase (GPDH) activity in 3T3-L1 cells by acting upon major adipocyte marker proteins such as PPARγ2, C/EBPα, and aP2 modulators. Furthermore, either CLA or PCLA stimulated basal, but not isoproterenol-sensitive, lipolysis in our cell model, suggesting that both CLA and PCLA may stimulate lipolysis via hormone sensitive lipase (HSL)-independent mechanisms. These results suggest that the PCLA may prove to be a stable pro-drug to control the deposition of fat in the human body, and that the anti-adipogenic effect of the PCLA on 3T3-L1 cells will offer a challenging approach for anti-obesity.

AB - This study is designed to evaluate whether the PEGylated conjugated linoleic acid (PCLA) as the pro-drug can have favorable stability, bioavailability, and anti-adipogenic activity in 3T3-L1 cells for anti-obesity when compared with conjugated linoleic acid (CLA) itself. The CLA was simply coupled to poly(ethylene glycol) (PEG) at the melting state without solvents or catalysts through ester linkages between the carboxylic group of CLA and the hydroxyl group of PEG. To confirm of PCLA as the pro-drug, CLA release from PCLA was investigated by using high-performance liquid chromatographic (HPLC), showing that CLA release from PCLA was almost 90% in a nearly continuous fashion over the next 75 h. Apoptosis was promoted by both CLA- and PCLA-treatments with increasing concentrations. However, the level of cell apoptosis induced by PCLA was lower than that induced by CLA owing to the biocompatible and hydrophilic properties of PEG. Moreover, the PCLA decreased glycerol-3-phosphate dehydrogenase (GPDH) activity in 3T3-L1 cells by acting upon major adipocyte marker proteins such as PPARγ2, C/EBPα, and aP2 modulators. Furthermore, either CLA or PCLA stimulated basal, but not isoproterenol-sensitive, lipolysis in our cell model, suggesting that both CLA and PCLA may stimulate lipolysis via hormone sensitive lipase (HSL)-independent mechanisms. These results suggest that the PCLA may prove to be a stable pro-drug to control the deposition of fat in the human body, and that the anti-adipogenic effect of the PCLA on 3T3-L1 cells will offer a challenging approach for anti-obesity.

KW - Adipocyte differentiation

KW - Anti-obesity

KW - Conjugated linoleic acid (CLA)

KW - Lipolysis

KW - PEGylation

KW - Poly(ethylene glycol) (PEG)

KW - Pro-drug

UR - http://www.scopus.com/inward/record.url?scp=33751436327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751436327&partnerID=8YFLogxK

U2 - 10.1016/j.abb.2006.10.002

DO - 10.1016/j.abb.2006.10.002

M3 - Article

VL - 456

SP - 19

EP - 29

JO - Archives of Biochemistry and Biophysics

JF - Archives of Biochemistry and Biophysics

SN - 0003-9861

IS - 1

ER -